Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders

A Multistakeholder Perspective on Advancing Individualized Therapeutics

A framework for individualized splice-switching oligonucleotide therapy

Consensus Guidelines for the Design and In Vitro Preclinical Efficacy Testing N-of-1

Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic later

New antisense oligonucleotide therapies reach first base in ALS

Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide

OTS Rare Disease N-of-1+ Briefing Document, Jan 2020

Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease

Drug Regulation in the Era of Individualized Therapies